CN107583035A - 一种重组人干扰素γ阴道膨胀栓及其制备方法 - Google Patents
一种重组人干扰素γ阴道膨胀栓及其制备方法 Download PDFInfo
- Publication number
- CN107583035A CN107583035A CN201711057756.XA CN201711057756A CN107583035A CN 107583035 A CN107583035 A CN 107583035A CN 201711057756 A CN201711057756 A CN 201711057756A CN 107583035 A CN107583035 A CN 107583035A
- Authority
- CN
- China
- Prior art keywords
- parts
- expansion plug
- vaginal expansion
- recombinant human
- human interferon
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101000599940 Homo sapiens Interferon gamma Proteins 0.000 title claims abstract description 62
- 102000043557 human IFNG Human genes 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title abstract description 20
- 239000011159 matrix material Substances 0.000 claims abstract description 41
- 229920000642 polymer Polymers 0.000 claims abstract description 23
- 239000000284 extract Substances 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 40
- 239000003814 drug Substances 0.000 claims description 32
- 241000972672 Phellodendron Species 0.000 claims description 21
- 235000008599 Poria cocos Nutrition 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 21
- 235000001188 Peltandra virginica Nutrition 0.000 claims description 20
- 241000246044 Sophora flavescens Species 0.000 claims description 20
- 239000000829 suppository Substances 0.000 claims description 20
- 239000010404 Scutellaria baicalensis extract Substances 0.000 claims description 19
- 238000001816 cooling Methods 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 14
- 150000002148 esters Chemical class 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000004745 nonwoven fabric Substances 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 238000007493 shaping process Methods 0.000 claims description 8
- 238000002604 ultrasonography Methods 0.000 claims description 8
- 229920001971 elastomer Polymers 0.000 claims description 7
- 239000000806 elastomer Substances 0.000 claims description 7
- -1 fatty acid ester Chemical class 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 229920002635 polyurethane Polymers 0.000 claims description 6
- 239000004814 polyurethane Substances 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 5
- 239000000194 fatty acid Substances 0.000 claims description 5
- 229930195729 fatty acid Natural products 0.000 claims description 5
- 244000197580 Poria cocos Species 0.000 claims 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 33
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000009471 action Effects 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 33
- 244000248825 Peltandra virginica Species 0.000 description 18
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 9
- 238000002156 mixing Methods 0.000 description 8
- 229920001577 copolymer Polymers 0.000 description 6
- 102100040018 Interferon alpha-2 Human genes 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 4
- 208000034530 PLAA-associated neurodevelopmental disease Diseases 0.000 description 4
- 201000008100 Vaginitis Diseases 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000155 melt Substances 0.000 description 4
- 210000001215 vagina Anatomy 0.000 description 4
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- 206010046914 Vaginal infection Diseases 0.000 description 3
- 229940079322 interferon Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000004626 polylactic acid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 241000218176 Corydalis Species 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000035126 Facies Diseases 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 description 1
- 241000896292 Odontothrips loti Species 0.000 description 1
- 244000080575 Oxalis tetraphylla Species 0.000 description 1
- 241000207929 Scutellaria Species 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920002627 poly(phosphazenes) Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000003239 susceptibility assay Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
编号 | 轴向膨胀值 | 径向膨胀值 | 重量差异 |
实施例1 | 1.95 | 1.93 | ±0.01% |
实施例2 | 1.91 | 1.90 | ±0.09% |
实施例3 | 1.88 | 1.87 | ±0.15% |
实施例4 | 1.85 | 1.86 | ±0.20% |
实施例5 | 1.81 | 1.82 | ±0.22% |
实施例6 | 1.78 | 1.81 | ±0.26% |
编号 | 4℃ | 25℃ | 37℃ |
实施例1 | 5.2×108 | 4.0×108 | 2.2×108 |
实施例2 | 5.0×108 | 3.6×108 | 1.3×108 |
实施例3 | 4.7×108 | 3.2×108 | 9.4×107 |
实施例4 | 4.6×108 | 2.7×108 | 8.6×107 |
实施例5 | 4.4×108 | 2.3×108 | 8.2×107 |
实施例6 | 4.1×108 | 1.9×108 | 7.7×107 |
对比例1 | 3.4×107 | 1.7×104 | 3.8×102 |
对比例2 | 3.7×107 | 3.3×104 | 4.2×102 |
对比例3 | 2.7×108 | 5.6×107 | 2.1×107 |
对比例4 | 2.5×108 | 6.1×107 | 1.7×107 |
对比例5 | 3.3×108 | 1.2×108 | 8.4×107 |
对比例6 | 3.5×108 | 1.1×108 | 8.7×107 |
编号 | 性状 | 标示量(%) | 融变时限(min) |
实施例1 | 黄色、光滑、未破裂 | 99.99 | 25 |
实施例2 | 黄色、光滑、未破裂 | 99.98 | 25 |
实施例3 | 黄色、光滑、未破裂 | 99.96 | 26 |
实施例4 | 黄色、光滑、未破裂 | 99.95 | 27 |
实施例5 | 黄色、光滑、未破裂 | 99.92 | 29 |
实施例6 | 黄色、光滑、未破裂 | 99.90 | 30 |
对比例1 | 黄褐色、粗糙、破裂、斑点 | 90.02 | 65 |
对比例2 | 黄褐色、粗糙、破裂、斑点 | 90.00 | 62 |
对比例3 | 黄色、光滑、未破裂 | 99.76 | 39 |
对比例4 | 黄色、光滑、未破裂 | 99.76 | 38 |
对比例5 | 黄色、光滑、未破裂 | 99.68 | 42 |
对比例6 | 黄色、光滑、未破裂 | 99.63 | 45 |
编号 | 释放时间(h) |
实施例1 | 24 |
实施例2 | 22 |
实施例3 | 20 |
实施例4 | 20 |
实施例5 | 18 |
实施例6 | 22 |
对比例1 | 6 |
对比例2 | 8 |
抑菌圈直径(mm) | 敏感度 |
大于20 | 极敏 |
15-20 | 高敏 |
10-14 | 中敏 |
1-10 | 低敏 |
0 | 不敏 |
编号 | 菌液浓度(cfu/g) | 抑菌圈直径(mm) | 敏感度 |
实施例1 | 105-106 | 28.84 | 极敏 |
实施例2 | 105-106 | 28.12 | 极敏 |
实施例3 | 105-106 | 27.76 | 极敏 |
实施例4 | 105-106 | 26.93 | 极敏 |
实施例5 | 105-106 | 26.21 | 极敏 |
实施例6 | 105-106 | 25.55 | 极敏 |
对比例3 | 105-106 | 12.29 | 中敏 |
对比例4 | 105-106 | 11.84 | 中敏 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711057756.XA CN107583035B (zh) | 2017-11-01 | 2017-11-01 | 一种重组人干扰素γ阴道膨胀栓及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711057756.XA CN107583035B (zh) | 2017-11-01 | 2017-11-01 | 一种重组人干扰素γ阴道膨胀栓及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107583035A true CN107583035A (zh) | 2018-01-16 |
CN107583035B CN107583035B (zh) | 2020-04-24 |
Family
ID=61045081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711057756.XA Active CN107583035B (zh) | 2017-11-01 | 2017-11-01 | 一种重组人干扰素γ阴道膨胀栓及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107583035B (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101313904A (zh) * | 2007-06-01 | 2008-12-03 | 北京德众万全药物技术开发有限公司 | 一种用于治疗外阴道炎的芬替康唑栓剂 |
CN103520338A (zh) * | 2013-10-11 | 2014-01-22 | 哈尔滨欧替药业有限公司 | 治糜康阴道膨胀栓及其制备方法和检测方法 |
CN103751098A (zh) * | 2013-12-31 | 2014-04-30 | 哈尔滨欧替药业有限公司 | 重组人干扰素α2а阴道膨胀栓及其制备方法和检测方法 |
CN104688947A (zh) * | 2015-02-12 | 2015-06-10 | 杨波 | 一种治疗阴道炎的中药药物 |
CN105012938A (zh) * | 2015-06-30 | 2015-11-04 | 哈尔滨欧替药业有限公司 | 重组人干扰素α2b阴道膨胀栓及其制备方法和检测方法 |
-
2017
- 2017-11-01 CN CN201711057756.XA patent/CN107583035B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101313904A (zh) * | 2007-06-01 | 2008-12-03 | 北京德众万全药物技术开发有限公司 | 一种用于治疗外阴道炎的芬替康唑栓剂 |
CN103520338A (zh) * | 2013-10-11 | 2014-01-22 | 哈尔滨欧替药业有限公司 | 治糜康阴道膨胀栓及其制备方法和检测方法 |
CN103751098A (zh) * | 2013-12-31 | 2014-04-30 | 哈尔滨欧替药业有限公司 | 重组人干扰素α2а阴道膨胀栓及其制备方法和检测方法 |
CN104688947A (zh) * | 2015-02-12 | 2015-06-10 | 杨波 | 一种治疗阴道炎的中药药物 |
CN105012938A (zh) * | 2015-06-30 | 2015-11-04 | 哈尔滨欧替药业有限公司 | 重组人干扰素α2b阴道膨胀栓及其制备方法和检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107583035B (zh) | 2020-04-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tiboni et al. | 3D printed clotrimazole intravaginal ring for the treatment of recurrent vaginal candidiasis | |
EP1629846B1 (en) | Topical use of probiotic bacillus spores to prevent or control microbial infections | |
JP2834951B2 (ja) | 細菌性腟症用予防および治療剤 | |
JP5425622B2 (ja) | 少なくとも1種のボツリヌス神経毒素及び少なくとも1種の鎮静剤誘導体の、治療上の、同時、分離、又は、順次的な使用 | |
CA2761947C (en) | Coated pharmaceutical capsule dosage form | |
US7507402B1 (en) | Topical use of probiotic Bacillus spores to prevent or control microbial infections | |
US20080089963A1 (en) | Topical compositions containing Bacillus coagulans extracellular products and uses thereof | |
US20080207737A1 (en) | Methods for the Treatment of Hyperhidrosis | |
JP2022123073A (ja) | Efpの治療または低減方法 | |
JPH11506451A (ja) | 医学的利用のためのマイクロカプセル封入されたラクトバシルス | |
CN107596350A (zh) | 一种重组人干扰素ε阴道膨胀栓及其制备方法 | |
US5068233A (en) | Synergistic combination of azelastine and theophylline or azelastine and α-mimetics | |
NZ301197A (en) | Transdermal formulation of xanomeline for treating alzeheimers disease | |
CN107583036A (zh) | 一种重组人干扰素α1b阴道膨胀栓及其制备方法 | |
CN107583035A (zh) | 一种重组人干扰素γ阴道膨胀栓及其制备方法 | |
EP1005862A1 (en) | Anti-chlamydia agents | |
CN101594869A (zh) | 可用于治疗感染性疾病的噻吨衍生物 | |
Olivos et al. | Entamoeba histolytica: mechanism of decrease of virulence of axenic cultures maintained for prolonged periods | |
CN115989025A (zh) | 用于缓解或治疗神经退行性疾病的症状的贴剂 | |
Virkkunen | Lipid research clinics coronary primary prevention trial results | |
EP1667622A2 (en) | Water dispersible film | |
WO2022221988A1 (en) | Pharmaceutical hydronidone formulations for diseases | |
CN112791046B (zh) | 一种具儿童安全保护功能的药物制剂和使用方法 | |
CN102423332B (zh) | 用于治疗青光眼的药物的制备方法 | |
CN115957243A (zh) | 脆弱拟杆菌在防治癌症相关腹泻中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211116 Address after: 150040 office building 7, Bohai Third Road, haping road concentration area, Harbin Economic Development Zone, Harbin, Heilongjiang Province Patentee after: Harbin Tianmei Pharmaceutical Co.,Ltd. Address before: 150069 No. 7, Bohai Third Road, Pingfang Industrial Zone, economic and Technological Development Zone, Harbin, Heilongjiang Province Patentee before: HARBIN OT PHARMACEUTICALS Co.,Ltd. Patentee before: Qiu Mingshi |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A recombinant human interferon g Vaginal expansion suppository and its preparation method Effective date of registration: 20230704 Granted publication date: 20200424 Pledgee: Harbin Kechuang Financing Guarantee Co.,Ltd. Pledgor: Harbin Tianmei Pharmaceutical Co.,Ltd. Registration number: Y2023230000060 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20200424 Pledgee: Harbin Kechuang Financing Guarantee Co.,Ltd. Pledgor: Harbin Tianmei Pharmaceutical Co.,Ltd. Registration number: Y2023230000060 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A recombinant human interferon gamma vaginal dilation suppository and its preparation method Granted publication date: 20200424 Pledgee: Harbin Kechuang Financing Guarantee Co.,Ltd. Pledgor: Harbin Tianmei Pharmaceutical Co.,Ltd. Registration number: Y2024230000040 |